About
Replimune Group Inc (NASDAQ:REPL) — investor relations, events, news, and company updates on 6ix.
Latest News
Yesterday
Replimune to Present at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
Apr 10 2026
Replimune Receives Complete Response Letter from the FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma
Feb 3 2026
Replimune Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update
Dec 18 2025
Replimune to Present at the 44th Annual J.P. Morgan Healthcare Conference
Nov 7 2025
Replimune Presents Late-Breaking Abstract and Additional Posters on RP1 at 40th Annual Meeting of the Society for the Immunotherapy of Cancer (SITC 2025)
Financials
Revenue
$0
Market Cap
$694.44 M
EPS
-3.44
Translate